Atigliflozin
Product Specifications
UNSPSC Description
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus[1].
Target Antigen
SGLT
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/atigliflozin.html
Solubility
10 mM in DMSO
Smiles
O[C@H]1[C@H](OC2=C(CC3=CC=C(OC)C=C3)SC=C2)O[C@H](CO)[C@@H](O)[C@@H]1O
Molecular Weight
382.43
References & Citations
[1]Schudok M, et al. The magic of small structure differences in a sodium-glucose cotransporter drug discovery project-14 C-labelled drug candidates in a key-differentiating study. J Labelled Comp Radiopharm. 2021 Feb;64(2):73-76.|[2]Bickel M, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-14810/Atigliflozin-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-14810/
Clinical Information
Phase 2
CAS Number
647834-15-9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
